Online inquiry

IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7949MR)

This product GTTS-WQ7949MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7949MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12884MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ12136MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ12213MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ13123MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ9591MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ13745MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ4256MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ4419MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-663513
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW